F. Hoffmann-La Roche AG


About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Roche retains sole responsibility for content © 2018 F. Hoffmann-La Roche AG. All trademarks used or mentioned in this release are protected by law.

1 August 2017 - 31 July 2018

Region: Global
Subject/journal group: All

The table to the right includes counts of all research outputs for F. Hoffmann-La Roche AG published between 1 August 2017 - 31 July 2018 which are tracked by the Nature Index.

Hover over the donut graph to view the FC output for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.

Note: Articles may be assigned to more than one subject area.

124 54.36

Outputs by subject (FC)

Subject AC FC
Life Sciences 94 38.79
Chemistry 30 15.54
Physical Sciences 1 0.02

Highlight of the month

The paradox of neuroimmune activation in ALS

© National Institutes of Health/Stocktrek Images/Getty

© National Institutes of Health/Stocktrek Images/Getty

Star-shaped support cells in the brain activate an immune response that helps protect against motor neuron loss in the early stages of amyotrophic lateral sclerosis (ALS). Yet, this same immune activation can accelerate neurodegeneration in later stages of the disease.

Findings from a mouse study, that included scientists from Roche, suggest that stage-dependent modulation of this immune process may be an effective therapeutic strategy for ALS patients.

The researchers activated a key cell-signaling pathway in the spinal cord astrocytes of a mouse model of ALS. They observed a proliferation of neuroimmune cells, called microglia, which resulted in delayed symptom onset but accelerated disease progression.

Pre-symptomatic treatment with an experimental Roche drug designed to enhance microglia function by blunting the immunosuppressive function of cannabinoid CB2 receptors led to a decrease in disease burden on a molecular level. A similar strategy could prove beneficial for those with a genetic risk for ALS who have yet to exhibit signs of the disease.

Supported content

  1. The EMBO Journal 37, e98697 (2018). doi: 10.15252/embj.201798697

View the article on the Nature Index

See more research highlights from F. Hoffmann-La Roche AG

More research highlights from F. Hoffmann-La Roche AG

1 August 2017 - 31 July 2018

International vs. domestic collaboration by FC

  • 10.84% Domestic
  • 89.16% International

Note: Hover over the graph to view the percentage of collaboration.

Note: Collaboration is determined by the fractional count (FC), which is listed in parentheses.

Affiliated joint institutions and consortia

Return to institution outputs